NCT03403465Active, not recruitingPhase 2
Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers
Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers ( Adaptive PET II)
Source: ClinicalTrials.gov · Last updated 22 Oct 2026
Brief summary (registry, in English)
This study expands on protocol (NCT01908504"PET adaptive RT") designed to evaluate the utility of adaptive PET-CT planning for radiation therapy (RT). Radiation therapy is used in many malignant diseases as a curative treatment modality. However, critical normal tissue is often in close approximation to disease, and portions of such tissue must receive high doses of radiation for appropriate treatment. Positron Emission Tomography (PET) adapted radiation therapy, as defined in the current protocol, may allow for a means of determining the eventual response to therapy, at a time point when adaptation of treatment plan may be possible to improve outcomes. This protocol will build upon the findings the previous protocol (NCT01908504 "PET adaptive RT") that evaluated the utility of intra-treatment PET imaging in multiple types of cancers. The current focus will be more specific to certain types of gastrointestinal and gynecologic cancers treated with RT, identified from the prior study to warrant further research.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (actual)
- First submitted
- 11 Jan 2018
- Start date
- 27 Mar 2018
- Primary completion date
- 5 Apr 2028
- Lead sponsor
- Duke University
- NCT number
- NCT03403465
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 90
- From 27 Mar 2018 to the primary completion date, 5 Apr 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Complete response by PET achieved with pre-radiation therapy treatment (surgery or chemotherapy)
Other illness
- No gross disease visible on imaging at the start of radiotherapy
Lab values
- Positive serum pregnancy test
Other
- Contraindication to PET
- Breast feeding
Who the study is looking for
- Pathologically (histologically or cytologically) proven diagnosis of cervical, vulvar, esophageal and anal canal cancer
- Patients with local or regional nodal disease are eligible
- Zubrod Performance Status 0, 1, or 2
- Age ≥ 18
- Negative serum pregnancy test for women of child bearing potential
- Patient must sign study-specific informed consent prior to study entry
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Duke University Medical Center Coordinator of this site? Confirm its status | Durham | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.